Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| RVMD - Revolution Medicines | 11.18% | Reduce −8.0% | 604,514 | $79.65 | $48M | −52,662 | +$17M |
| XBI - Spdr S&P Biotech ETF | 9.53% | Reduce −16.2% | 336,505 | $121.93 | $41M | −65,000 | +$799K |
| STXS - Stereotaxis | 7.31% | Hold | 13,680,554 | $2.30 | $31M | — | — |
| ATRC - Atricure | 5.49% | Add +0.9% | 597,431 | $39.56 | $24M | +5,158 | +$3M |
| CYTK - Cytokinetics | 5.48% | Reduce −6.1% | 370,997 | $63.54 | $24M | −23,943 | +$2M |
| IDYA - Ideaya Biosciences | 4.07% | Reduce −6.1% | 506,740 | $34.57 | $18M | −33,183 | +$3M |
| AXGN - Axogen | 3.63% | Reduce −35.8% | 476,826 | $32.73 | $16M | −265,456 | +$2M |
| XENE - Xenon Pharmaceuticals | 3.00% | Hold | 287,939 | $44.82 | $13M | — | — |
| NDAQ - Ishares Nasdaq Biotech Indx | 2.67% | Reduce −33.6% | 68,095 | $168.77 | $11M | −34,405 | −$3M |
| BHVN - Biohaven | 2.51% | Add +306.1% | 955,235 | $11.29 | $11M | +720,000 | +$7M |
| RCUS - Arcus Biosciences | 2.39% | Reduce −31.3% | 431,329 | $23.83 | $10M | −196,297 | +$2M |
| NBIX - Neurocrine Biosciences | 2.33% | Hold | 70,615 | $141.83 | $10M | — | — |
| DAWNGBX — | 2.16% | Hold | 999,163 | $9.32 | $9M | — | — |
| TNDM - Tandem Diabetes Care | 1.81% | Hold | 355,208 | $21.98 | $8M | — | — |
| ASND - Ascendis Pharma A/S | 1.40% | Reduce −15.1% | 28,177 | $213.24 | $6M | −5,000 | −$587K |
| DXCM - Dexcom | 1.36% | Add +34.7% | 88,279 | $66.37 | $6M | +22,727 | +$1M |
| SNDX - Syndax Pharmaceuticals | 1.36% | Reduce −44.5% | 277,855 | $21.01 | $6M | −222,847 | −$2M |
| Kalvista Pharmaceuticals | 1.34% | Reduce −15.6% | 356,802 | $16.15 | $6M | −65,929 | +$613K |
| CMPS - Compass Pathways | 1.30% | Hold | 811,046 | $6.90 | $6M | — | — |
| INGN - Inogen | 1.29% | Add +36.6% | 827,071 | $6.72 | $6M | +221,446 | +$610K |
| DNLI - Denali Therapeutics | 1.22% | Add +89.0% | 318,500 | $16.51 | $5M | +150,000 | +$3M |
| MBX - Mbx Biosciences | 1.21% | Add +94.4% | 165,265 | $31.54 | $5M | +80,265 | +$4M |
| BCAX - Bicara Therapeutics | 1.02% | Reduce −17.5% | 261,583 | $16.83 | $4M | −55,418 | −$603K |
| LKFT - Galapagos | 0.99% | Hold | 130,175 | $32.70 | $4M | — | — |
| CATBUSD - Astria Therapeutics | 0.93% | Reduce −4.7% | 304,775 | $13.09 | $4M | −15,000 | +$2M |
| EWTX - Edgewise Therapeutics | 0.92% | Reduce −25.3% | 159,736 | $24.82 | $4M | −54,000 | +$497K |
| IMVT - Immunovant | 0.89% | Reduce −21.4% | 150,524 | $25.42 | $4M | −40,969 | +$739K |
| PRCT - Procept Biorobotics | 0.88% | New | 120,000 | $31.46 | $4M | +120,000 | +$4M |
| CYBN - Cybin | 0.86% | New | 455,018 | $8.18 | $4M | +455,018 | +$4M |
| ALKS - Alkermes | 0.85% | Reduce −3.3% | 130,248 | $27.98 | $4M | −4,500 | −$398K |
| LRMR - Larimar Therapeutics | 0.83% | Reduce −8.6% | 939,164 | $3.81 | $4M | −88,600 | +$259K |
| STOK - Stoke Therapeutics | 0.80% | Reduce −35.9% | 108,875 | $31.74 | $3M | −60,916 | −$534K |
| LXEO - Lexeo Therapeutics | 0.79% | Reduce −4.8% | 340,859 | $9.93 | $3M | −17,224 | +$1M |
| BCRX - Biocryst Pharmaceuticals | 0.76% | Add +91.6% | 418,255 | $7.80 | $3M | +200,000 | +$2M |
| NKTR - Nektar Therapeutics | 0.74% | Add +36.4% | 74,998 | $42.28 | $3M | +20,000 | +$42K |
| PRQR - Proqr Therapeutics | 0.74% | Hold | 1,567,561 | $2.02 | $3M | — | — |
| IPSC - Century Therapeutics | 0.65% | Add +63.9% | 2,793,586 | $0.9948 | $3M | +1,089,354 | +$2M |
| Immatics | 0.64% | Add +11.1% | 261,138 | $10.50 | $3M | +26,138 | +$740K |
| GPCR - Structure Therapeutics | 0.60% | Reduce −37.3% | 37,000 | $69.55 | $3M | −22,000 | +$921K |
| MPLT - Maplight Therapeutics | 0.59% | New | 143,764 | $17.57 | $3M | +143,764 | +$3M |
| ALGN - Align Technology | 0.58% | Add +45.5% | 16,000 | $156.15 | $2M | +5,000 | +$1M |
| KURA - Kura Oncology | 0.57% | Reduce −49.1% | 235,868 | $10.39 | $2M | −227,500 | −$2M |
| AQST - Aquestive Therapeutics | 0.56% | Reduce −26.7% | 375,915 | $6.46 | $2M | −136,674 | −$437K |
| RAPP - Rapport Therapeutics | 0.53% | Hold | 75,000 | $30.34 | $2M | — | — |
| PROF - Profound Medical | 0.52% | New | 285,710 | $7.87 | $2M | +285,710 | +$2M |
| SPRY - Ars Pharmaceuticals | 0.51% | Add +35.3% | 190,065 | $11.65 | $2M | +49,565 | +$802K |
| Mediwound | 0.49% | Hold | 113,612 | $18.46 | $2M | — | — |
| VKTX - Viking Therapeutics | 0.49% | Reduce −7.8% | 59,516 | $35.18 | $2M | −5,000 | +$398K |
| PODD - Insulet | 0.45% | Hold | 6,870 | $284.24 | $2M | — | — |
| ALLO - Allogene Therapeutics | 0.44% | Hold | 1,380,118 | $1.37 | $2M | — | — |
| CLDX — | 0.43% | Add +179.5% | 68,518 | $27.16 | $2M | +44,000 | +$1M |
| TELA - Tela Bio | 0.39% | Hold | 1,441,029 | $1.18 | $2M | — | — |
| Engene | 0.34% | New | 163,645 | $9.03 | $1M | +163,645 | +$1M |
| VRCA - Verrica Pharmaceuticals | 0.33% | New | 173,451 | $8.31 | $1M | +173,451 | +$1M |
| ALEC - Alector | 0.33% | Add +13.8% | 908,351 | $1.56 | $1M | +110,000 | −$946K |
| MLYS - Mineralys Therapeutics | 0.32% | Reduce −53.9% | 38,490 | $36.29 | $1M | −45,000 | −$2M |
| ANNX - Annexon | 0.32% | New | 272,812 | $5.02 | $1M | +272,812 | +$1M |
| ORIC - Oric Pharmaceuticals | 0.27% | Add +34.8% | 141,045 | $8.18 | $1M | +36,374 | −$102K |
| ARAY - Accuray | 0.27% | Add +14.2% | 1,395,508 | $0.8246 | $1M | +173,150 | −$891K |
| ERAS - Erasca | 0.22% | Reduce −27.3% | 254,436 | $3.72 | $947K | −95,564 | +$184K |
| Polypid | 0.21% | Hold | 207,900 | $4.34 | $902K | — | — |
| INSP - Inspire Medical Systems | 0.18% | Reduce −50.0% | 8,600 | $92.23 | $793K | −8,600 | −$483K |
| ACET - Adicet Bio | 0.18% | New | 93,812 | $8.42 | $790K | +93,812 | +$790K |
| FHTX - Foghorn Therapeutics | 0.16% | Hold | 126,859 | $5.40 | $685K | — | — |
| BNTX - Biontech Se | 0.15% | Hold | 7,000 | $95.20 | $666K | — | — |
| NGNE - Neurogene | 0.13% | Reduce −7.9% | 27,974 | $20.60 | $576K | −2,401 | +$50K |
| FATE - Fate Therapeutics | 0.13% | New | 550,000 | $0.9826 | $540K | +550,000 | +$540K |
| OBIO - Orchestra Biomed | 0.12% | Reduce −65.1% | 126,841 | $4.15 | $526K | −236,795 | −$375K |
| BCYC - Bicycle Therapeutics | 0.11% | Hold | 64,492 | $7.08 | $457K | — | — |
| Compugen | 0.10% | Hold | 272,402 | $1.53 | $417K | — | — |
| KPTI - Karyopharm Therapeutics | 0.09% | New | 51,000 | $7.36 | $375K | +51,000 | +$375K |
| RARE - Ultragenyx Pharmaceutical | 0.09% | New | 16,000 | $23.00 | $368K | +16,000 | +$368K |
| AUTL - Autolus Therapeutics | 0.08% | Hold | 179,316 | $1.99 | $357K | — | — |
| ADCT - Adc Therapeutics SA | 0.06% | Reduce −36.9% | 77,081 | $3.53 | $272K | −45,000 | −$216K |
| BWAY - Brainsway | 0.06% | Reduce −77.2% | 12,965 | $19.02 | $247K | −44,001 | −$612K |
| CATX - Perspective Therapeutics | 0.03% | New | 50,000 | $2.75 | $138K | +50,000 | +$138K |
Showing top 50 of 76 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Merus Bv | 5.13% | Exit | 0 | $94.15 | $21M | −220,451 | −$21M |
| SLNOEUR - Soleno Therapeutics | 0.89% | Exit | 0 | $67.60 | $4M | −53,000 | −$4M |
| CMPX - Compass Therapeutics | 0.82% | Exit | 0 | $3.50 | $3M | −946,661 | −$3M |
| Korro Bio | 0.72% | Exit | 0 | $47.89 | $3M | −60,804 | −$3M |
| Keros Therapeutics | 0.32% | Exit | 0 | $15.82 | $1M | −80,716 | −$1M |
| BDTX — | 0.29% | Exit | 0 | $3.79 | $1M | −307,070 | −$1M |
| URGN - Urogen Pharma | 0.14% | Exit | 0 | $19.95 | $549K | −27,515 | −$549K |
| Sutro Biopharma | 0.09% | Exit | 0 | $0.8694 | $380K | −437,079 | −$380K |
| Biomx | 0.05% | Exit | 0 | $0.5260 | $211K | −401,136 | −$211K |
| APRE - Aprea Therapeutics | 0.05% | Exit | 0 | $1.47 | $202K | −137,174 | −$202K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2